Диссертация (1173577), страница 51
Текст из файла (страница 51)
544 F.3d 1341 (Fed. Cir. 2008).38.U.S. Supreme Court, KSR International v. Teleflex, 550 U.S. _; 127 S.Ct.1727 (2007). URL: https://www.supremecourt.gov/opinions/06pdf/04-1350.pdf (датаобращения: 08.09.2017).39.U.S. Supreme Court, Brenner v. Manson, 383 U.S. 519 (1966). URL:https://casetext.com/case/brenner-v-manson (дата обращения: 30.04.2017).40.U.S. Supreme Court, Funk Prothers Seed Co. v. Kalo Inoculant Co., 333U.S. 127 (1948).41.United States Court of Appeals, Federal Circuit.
In re Fisher 421 F. 3d1365. URL: https://casetext.com/case/in-re-fisher-6 (дата обращения: 30.04.2017).42.United States Court of Appeals, Federal Circuit. Novo Nordisk Pharms. V.Bio-TechnologyGeneralCorp.,424F.3d1347(Fed.https://casetext.com/case/novo-nordisk-v-bio-technology-generalCir.2005). URL:(датаобращения:30.04.2017).43.United States Court of Appeals, Federal Circuit. Therasense, Inc. v.Becton, Dickinson and Co. 649 F. 3d 1276 – Court of Appeals, Federal Circuit, 2011.URL: https://casetext.com/case/therasense-inc-now-known-as-abbott-diabetes-care-incv-becton (дата обращения: 30.04.2017).24444.United States Court of Appeals, Federal Circuit.
Wyeth v. Kappos, No.2009-1120, 2010 U S App. Lexis 300, 2010 WL 27184 (Fed. Cir. Jan. 7, 2010).45.AGvUnited States Court of Appeals, Federal Circuit, Bayer Schering PharmaLupin,676F.3d1316,1328(Fed.Cir.https://casetext.com/case/warner-lambert-co-v-apotex-corp2012).(датаURL:обращения:02.01.2017).46.05-1114United States Court of Appeals, Federal Circuit, Bonzel v. Pfizer, Inc., No.(Fed.Cir.Mar.2,2006).URL:http://www.finnegan.com/files/Publication/1b90490a-ed1e-4989-b183bff74540b852/Presentation/PublicationAttachment/a2011686-5840-4e98-80a9c1de0ee55156/05-1114%203-2-06.pdf (дата обращения: 30.04.2017).47.U.S. Court of Appeals for the Federal Circuit, Roche Products, Inc. v.Bolar Pharmaceuticals Co., Inc.,- 733 F.2d 858 (Fed.
Cir. 1984), April 23, 1984. URL:http://law.justia.com/cases/federal/appellate-courts/F2/733/858/459501/(датаобращения: 10.04.2016).48.Supreme Court of the United States, Caraco Pharmaceutical Labs, Ltd. vNovo Nodrisk A/S et.al., 132 S. Ct. 1670 (2012).49.U.S. Court of Appeals for the Sixth Circuit - In re Cardizem CD litigation,332 F.3d 896 (6th Cir. 2003).50.United States Court of Appeals, Federal Circuit, Warner-Lambert Co. v.Apotex Corp., 394 F. 3d 1348 (Fed.
Cir. 2003). URL: https://casetext.com/case/warnerlambert-co-v-apotex-corp (дата обращения: 02.01.2017).51.U.S. District Court for the District of New Jersey, December 18, 2002,Organon v. Teva, 244 F. Supp. 2d 370, 373 (D.N.J. 2002).52.United States Court of Appeals, Federal Circuit, Peppenhausen v.
Falke, 19Fed. Cas. 1048, 1049 (C.C.S.D.N.Y. 1861) (No. 11, 279).53.United States Court of Appeals for the Third Circuit In re K-Dur AntitrustLitig., No. 10-2078, slip op. (3d Cir. July 16, 2012).245Другие материалы1.ВТОДоклад Рабочей группы по присоединению Российской Федерации котноября16года.2011URL:inform.ru/upload/documents/report_of_working_group_orig.htm(датаhttp://wtoобращения:30.04.2017).2.SectorInquiryReport.URL:http://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/index.html(датаобращения: 30.04.2017).3.РекомендациипогармонизацииЕвропейскогоиРоссийскогозаконодательства по вопросам дополнительной патентной охраны Д-р Мартин деЛанге,Голландскоепатентноеведомство.URL:http://www.rupto.ru/activities/inter/bicoop/rus_es/comp5/rekom.pdf (дата обращения:30.04.2017).4.РуководствоВОЗпооценкеподобныхбиотерапевтическихпрепаратов, 2009.
34 с. Guidelines on Evaluation of Similar Biotherapeutic Products(SBPs), WHO Expert Committee on Biological Standardization. Geneva, 19 to 23October 2009. URL: http://www. who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf (дата обращения: 30.04.2017).5.Communication from the Commission — Guidelines on the application ofArticle 101 of the Treaty on the Functioning of the European Union to technologytransfer agreements URL: http://eur-lex.europa.eu/legalcontent/EN/TXT/?uri=CELEX:52014XC0328(01) (дата обращения: 30.04.2017).6.medicinalEuropean Medicines Agency policy on publication of clinical data forproductsforhumanuse2October2014EMA/240810/2013.URL: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2014/10/WC500174796.pdf (дата обращения: 30.04.2017).7.European Commission 2007 “Notice3 to applicants”, p.29.
URL:http://ec.europa.eu/health/files/eudralex/vol-6/a/vol6a_chap1_2007-01_en.pdfобращения: 02.01.2016).(дата2468.EuropeanPatentOfficeAnnualReport2006.URL:http://www.epo.org/about-us/office/annual-reports.html (дата обращения: 30.04.2017).9.MedicinesDelivery past due: global precedent set under Canada’s Access toRegime,Vol.13,Number1,July2008.http://www.aidslaw.ca/site/wp-content/uploads/2013/04/CAMR_131-e.pdfURL:(датаобращения: 30.04.2017).10.European Commission, Communication from the Commission - ExecutiveSummary of the Pharmaceutical.11.Examination of Patent Applications That Include Claims ContainingAlternative Language Federal Register / Vol.
72, No. 154 / Friday, August 10, 2007 /Proposed Rules. URL: https://www.uspto.gov/sites/default/files/web/offices/com/sol/notices/72fr44992.pdf (дата обращения: 30.04.2017).12.Federal Trade Commission. Comment off the Staff of the Bureau ofCompetition and of Policy Planning of the Federal Trade Commission, 1999. DocketNo.
85N-0214. 6 January 2005. URL: http://www.ftc.gov/be/v990016.htm (датаобращения: 30.04.2017).13.Federal Trade Commission Staff Report, “Pay-for-delay: How drugcompany pay-offs cost consumers billions” A Federal Trade Commission Staff Study,January 2010. URL: https://www.ftc.gov/reports/pay-delay-how-drug-company-payoffs-cost-consumers-billions-federal-trade-commissionstaff (дата обращения: 30.04.2017).14.Federal Trade Commission.
To promote innovation: the proper balance ofcompetition and patent law and policy (2003).15.Generic Drug Savings in the U.S. Fourth Annual Edition, The GenericPharmaceutical Association.: 2012.16.Manual of Patent Examining Procedure. 9th Edition, March 2014. Theofficial Website of the United States Patent and Trademark Office. URL:http://www.uspto.gov/web/offices/pac/mpep/index.htm (дата обращения: 01.04.2015).24717.NIHCM Foundation. Prescription drugs and intellectual propertyprotection, issue brief, August 2000. URL: https://www.nihcm.org/pdf/prescription.pdf(дата обращения: 30.04.2017).18.NDCHealth.NDCHealth:2003YearinReview.URL:www.ndchealth.com/pdf/NDCHealthYIR_ 2003_0604.ppt (based on data from NDCPharmaceutical Audit Suite (PHAST)).
Atlanta GA, 2003.19.Pay-for-Delay Deals: Limiting Competition and Costing Consumers. FTC.Washington, D.C. July 23, 2013.20.Pharmaceutical Sector Inquiry Report, 2008, European Commission.21.Qualification Process for Drug Development Tools U.S. Department ofHealth and Human Services Food and Drug Administration Center for Drug EvaluationandResearch(CDER)January2014Proceduralhttp://www.fda.gov/forpatients/approvals/drugs/default.htm//URL:обращения:(дата30.04.2017).22.Report on the Statutory Review of Sections 21.01 to 21.19 of the PatentAct - Canada's Access to Medicines Regime CAMR), Government of Canada,December 14, 2007.
URL: https://www.canada.ca/en/health-canada/services/canadaaccess-medicines-regime.html (дата обращения: 30.04.2017).23.United Nations Conference on Trade and Development (UNCTAD), TheInternational Patent System as an Instrument of Policy for National Development,(TD/B/C.6/AC.2/3 Geneva, 1975).24.SantaClaraComputer&HighTech.http://papers.ssrn.com/sol3/papers.cfm?abstract_id=989611L.J.,p.(дата489.URL:обращения:30.04.2017).25.SectorInquiryReport.http://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/index.htmlURL:(датаобращения: 30.04.2017).26.United Nations Conference on Trade and Development (UNCTAD),“Major Issues Arising from the Transfer of Technology to Developing Countries”248(1975b) TD/B/AC.11/10/Rev.2 United Nations publications, Report by the UNCTADSecretariat.27.World Health Organization.
Global Price Reporting Mechanism for HIV,tuberculosis,andmalaria.Geneva:WHO;c2015,Jan13.URL:http://www.who.int/hiv/amds/gprm/en/ (дата обращения: 30.04.2017).28.United States Patent and Trademark office. Examination guidelines fordetermining obviousness under 35 U.S.C. 103 in view of the Supreme Court Decisionin KSR International Co. v. Teleflex Inc. Federal register, Vol. 72, No. 195 oct 10,2007.29.US Dept, of Health & Human Servs. Et. Al.
(2010), Electronic orangebook: Approved drug products with therapeutic equivalence evaluations.30.BroaderU.S. Food and Drug Administration. FDA Talk Paper. FDA SupportsAccesstoLowerPricesDrugs,2005.http://www.fda.gov/bbs/topics/answers/2004/ans01296.html30.04.2017).30March(дата2006.URL:обращения:.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
